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cell invasionElucidating the mechanism of prostate cancer cell invasion may lead to the identiﬁcation of novel therapeutic
strategies for its treatment. Paired box 2 (PAX2) and hepatocyte growth factor (HGF) proteins are promoters
of prostate cancer cell invasion. We found that PAX2 protein activated the HGF gene promoter through histone
H3 acetylation and upregulated HGF gene expression. Deletion analysis revealed that the region from−637 to
−314 of the HGF gene was indispensable for HGF promoter activation by PAX2. This region contains consensus
PAX2 binding sequences and mutations of the sequences attenuated HGF promoter activation. Using an in vitro
invasion model, we found that PAX2 and HGF promoted prostate cancer cell invasion in the same pathway.
Knockdown of HGF expression attenuated the cells' invasive capacity. Moreover, in tissue samples of human
prostate cancers, HGF and PAX2 expression levelswere positively correlated. These results suggested that upreg-
ulation ofHGF gene expression by PAX2 enhanced the invasive properties of prostate cancer cells. The PAX2/HGF
pathway in prostate cancer cells may be a novel therapeutic target in prostate cancer patients.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Cancer cell invasion is an important step inmetastasis, a process that
requires multiple steps [1,2]. Uncovering the mechanism of cancer cell
invasion is crucial for identifying new therapeutic targets. Previously,
we reported that paired box 2 (PAX2) protein functioned as a promoter
of prostate cancer cell invasion [3]. PAX2 is a member of the PAX gene
family. There are nine PAX genes in humans, and they are divided into
four groups according to their structure [4]. PAX genes code for
transcription factors and they regulate the development of various tis-
sues through their modulation of target gene expression. Functional
dysregulation of PAX genes is also known to be associated with the
progression of cancer. Hyper-expression of PAX2 was observed in
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, Japan.invasiveness of prostate cancer cells in in vitro assays [3]. The expression
levels of several cadherins were downregulated by PAX2 knockdown.
Cadherin, which is expressed in the plasma membrane of cells, is a
meditator of cell–cell adhesion. Dysregulation of cadherin expression
occurs during cancer cell invasion [5,6]. In kidney cancer cell lines,
several direct target genes of PAX2 protein, such as ADAM10 [7] and
the Wilms tumor suppressor gene 1 (WT1) [8] have been reported. In
prostate cancer cells, genes directly targeted by PAX2 protein remain
to be identiﬁed. Analysis of the target genes of PAX2 protein in prostate
cancers cells may lead to better understanding of the mechanism of
prostate cancer cell invasion.
Some intracellular signal pathways promoting cancer cell invasion
are thought to be the same as those promoting migration and cell
growth during embryogenesis and tissue repair [4,9]. Hepatocyte
growth factor (HGF) is a ligand of the Met receptor, a transmembrane
receptor tyrosine kinase and a growth factor for epithelial cells. HGF
activates Shp2 Ras and ERK/MAPK pathways by association with the
Met receptor. Receptor activation induces invasion, migration and
proliferation of cells during development and regeneration, especially
in the liver [9]. Dysregulation of HGF and Met signaling is observed in
metastasis of cancer cells [10]. HGF is known to promote invasion of
cells such as Madin–Darby canine kidney (MDCK) cell lines in in vitro
assays [11]. Recombinant HGF treatment of MDCK cells increased the
E-cadherin protein level [12]. It was reported that HGF produced by
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human androgen-independent prostate cancer (AIPC) cell line. In an
autocrine manner, 22Rv1 cells produce their own HGF that induces
cell growth through activation of the Met receptor [14]. In pancreatic
β-cells, interleukin-6 and glucocorticoids activate the HGF promoter
through enhanced binding of STAT3 to the HGF promoter [15]. Here,
we investigated the mechanism underlying HGF expression in prostate
cancer cells with the intent of better understanding the process of
prostate cancer progression. We focused on the in vitro relationship
between PAX2 and HGF using prostate cancer cell lines.
2. Material and methods
2.1. siRNA
siRNAs targeting PAX2 (HSS107605 and HSS10706) and those
targeting HGF (HSS179212, HSS179213 and HSS179214) were pur-
chased from Invitrogen. Nonspeciﬁc control siRNA was also purchased
from Ambion (catalogue number 12935-200) and used as siControl.
Each experiment was performed using all the above siRNAs to conﬁrm
the results. The results obtained using siPAX2 (HS107605) and siHGF
(HSS179212) are shown in the ﬁgures.
2.2. Antibodies
Antibodies used to target speciﬁc proteins were as follows: IgG
(I5006, Sigma), PAX2 (9666, Cell Signaling Technology, Danvers, MA,
USA), HGF (24865, Abcam, Cambridge, MA, USA), acetyl-histone H3
(06-599, Millipore, Temecula, CA, USA) and β-actin (A5441, Sigma, St.
Louis, MO, USA). Peroxidase-conjugated secondary antibodies for
immunoblot were purchased from Jackson Immuno Research (West
Grove, PA, USA) or GE Healthcare (Pittsburgh, PA, USA).
2.3. Plasmids
FLAG-tagged fused human PAX2 isoform c (NCBI Reference Sequence:
NM_003988.3) was inserted into the pcDNA3 vector (Invitrogen). A
reporter plasmid, HGF-luc, was constructed by inserting the upstream
region of the HGF gene into the pGL3-basic vector (Promega, Madison,
WI, USA).
2.4. Cell culture and transfection
The 22Rv1 cell line was purchased from ATCC and cultured in RPMI
1640 with 10% fetal bovine serum (FBS). PC3 and LNCaP cell lines were
provided by the RIKEN BRC (the National Bio-resource Project of the
MEXT, Japan) and were cultured in RPMI 1640 with 10% fetal bovine
serum (FBS). For knockdown of speciﬁc genes in 22Rv1 cells, transfection
of siRNAwas performedusing Lipofectamine RNAiMAX (Invitrogen)with
antibiotic-freemedium formore than 3 days. The efﬁcacy of silencingwas
assessed by both by qPCR and western blotting. Transfection of cDNAs
into PC3 cell was performed using Lipofectamine 2000 (Invitrogen) for
20–72 h.
2.5. Invasion assays
Matrigel invasion assays were performed using uncoated or
Matrigel-coated Transwell inserts (Becton Dickinson, East Rutherford,
NJ, USA) according to the manufacturer's instructions as previously
described [3,16]. Two days after 22Rv1 cells had been transfected with
each siRNA, 2.5 × 105 live cells were added to the inserts. Cells were
incubated with or without 100 mM recombinant HGF (TP315593,
OriGene, Rockville, MD, USA) at 37 °C in a humidiﬁed 5% CO2 atmo-
sphere for 24 h. Cells that had invaded through the inserts were stained
using a Diff-Quik staining kit (Sysmex, Hyogo, Japan), and the total
number of stained cells was counted.2.6. Quantitative RT-PCR
One microgram of total RNA was extracted from each sample using
TRIzol (Invitrogen). RNA was transcribed into ﬁrst-strand cDNA using
PrimeScript RT Master Mix (Takara). Quantitative RT-PCR was
performed using a Thermal Cycler Dice TP900. Primer sets for PCR are
as follows:Gene SequenceAX2 (3′-UTR)
used in Figs. 1A, C and Fig. 6Forward 5′-CCCAGCGTCTCTTCCATCA-3′
Reverse 5′-GGCGTTGGGTGGAAAGG-3′AX2 (ORF)
used in Fig. 1DForward 5′-CCCAGCGTCTCTTCCATCA-3′
Reverse 5′-GGCGTTGGGTGGAAAGG-3′GF Forward 5′-TGGTGTGAATCCAGTAGTCCCATTT-3′
Reverse 5′-CGCCGCCCTATATTCTGTGGA-3′APDH Forward 5′-ACCACAGTCCATGCCATCAC-3′
Reverse 5′-TCCACCACCCTGTTGCTGTA-3′2.7. Western blotting
Whole cell lysates were extractedwith lysis buffer (10mMTris–HCl
[pH 7.8], 1%NP40, 0.15MNaCl, 1mMEDTA).Western blottingwas then
performed using standard methods [17].
2.8. Chromatin immunoprecipitation (ChIP) assay
Cells were ﬁxed with 1% formalin for 10 min at 37 °C. Cell pellets
were diluted with 1% sodium dodecyl sulfate (SDS), 10 mM EDTA
(pH 7.9), and 50 mM Tris–HCl (pH 8.1) and reacted with 0.3 U/μL
MNase (Takara) for 10 min at 4 °C. ChIP assays were performed using
previously reported protocols [17]. ImmunoprecipitatedDNA fragments
were ampliﬁed with several primer sets and quantiﬁed with Thermal
Cycler Dice TP900 (Takara). Primer sets for PCR are described as follows:Primers Sequenceegion-a Forward 5′-TATGCTGCTTCCCCTTCCTC-3′
Reverse 5′-GATCCCAGTGGCTCCTATCC-3′egion-b Forward 5′-CGAGTGAGGAAAGGAGGGG-3′
Reverse 5′-GTGCCTAAAAGAGCCAGTCG-3′egion-c Forward 5′-TTTTGTGAAGTGGCCCGTTT-3′
Reverse 5′-CGACCCTGTGAAGCGATTTT-3′2.9. Luciferase assay
PC3 cells (70% conﬂuent) were transfected with PAX2 expression
plasmids and reporter plasmids using Lipofectamine for 20 h. As a
reference plasmid to normalize transfection efﬁciency, pRL-CMV
plasmid (Promega) was cotransfected in all experiments. After 24 h of
transfection, total RNA was isolated, subjected to RT, and quantiﬁed by
real-time PCR [18]. All values are the means ± standard deviations of
at least 3 independent experiments. The primers are as follows:Primers Sequencereﬂy luciferase Forward 5′-AAGGTTGTGGATCTGGATAC-3′
Reverse 5′-GATTGTTTACATAACCGGAC-3′enilla luciferase Forward 5′-CTTCGTGGAAACCATGTTGCC-3′
Reverse 5′-CTTCGTGGAAACCATGTTGCC-3′,2.10. DNA pull-down assay
DNApull-down assayswere performed as previously described [19].
Dynabeads M-280 Streptavidin (250 μg; Invitrogen) were washed in
buffer A (10 mM Tris–HCl pH 7.5, 1 mM EDTA, 2 M NaCl). They were
then incubated with annealed 5′-biotinylated oligonucleotides
(125 pmol) for 15 min at room temperature in buffer A. Beads
were then washed twice with buffer A and three times with buffer C
2469T. Ueda et al. / Biochimica et Biophysica Acta 1852 (2015) 2467–2473(20 mM Tris–HCl pH 8.0, 1 mM EDTA, 10% glycerol, 1 mM DTT, 50 mM
NaCl). Beads (250 μg) were incubated in buffer C with 0.05 mg/mL
poly(dI-dC) and 10 μL of recombinant PAX2 for 15min at room tempera-
ture andwashedwith buffer C. Proteinswere then analyzed by SDS-PAGE
and immunoblots using anti-PAX2 antibody. 5′-Biotinylated oligonucleo-
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Antisense 5′-Bio-CGCTCAATATCAAGAGCGGAATACA-3′.Recombinant PAX2 was expressed using an in vitro translation
system according to the manufacturer's instructions (Promega).2.11. Patient tumor samples
Human prostate tumor samples were obtained from University
Hospital, Kyoto Prefectural University of Medicine, in accordance with
the protocols approved by the hospital's Institutional Ethical Committee.
Written informed consent was obtained from each patient. Tumor sam-
pleswere taken from freshly isolated surgical resections or needle biopsy.2.12. Statistical analysis
Statistical analyses were carried out by a t-test as appropriate. All
data are reported as means ± SD. A P-value of b0.05 was considered
signiﬁcant.pression levels in prostate cancer cells. (A) Regulation ofHGF gene
easure the expression levels of the HGF and the PAX2 genes. Eac
els of GAPDHmRNA. *P b 0.05. (B) Immunoblots using PAX2- or HG
ression levels among various cell lines. The expression of PAX2 re
were transfectedwith PAX2 expression plasmid or an insert-less
uced three times.3. Results
3.1. PAX2 increased the HGF expression level in prostate cancer cells
Previously, we performed genomic screening to identify PAX2 target
genes by DNA microarray analysis using PAX2-knockdown 22Rv1 cells
which expressed PAX2 at higher level than other prostate cancer cell
lines [3]. A total of 645 genes among the tested 28,768 genes exhibited
a more than 2-fold decrease in mRNA expression, including HGF. To
verify the results of the gene array experiments, we used quantitative
PCR (qPCR) to measure the expression of HGF. We found that the
mRNA expression level of HGFwas indeed reduced in PAX2 knockdown
cells (Fig. 1A). Protein levels of HGFwere also reduced by knockdown of
PAX2 (Fig. 1B). Notably, the PAX2 expression level was not altered by
knockdown of HGF (Fig. 1A, B). Next, we compared expression level of
PAX2 and HGF between different prostate cancer cell lines (Fig. 1C).
The 22Rv1 cell line is derived from a human primary prostate cancer
[20]. PC3 and LNCaP cell lines are derived fromprostate cancer cells me-
tastasized to bone and lymph node, respectively [21,22]. qPCR results
showed that 22Rv1 cells expressed both PAX2 and HGF at higher level
than PC3 and LNCaP cells. To conﬁrm that overexpression of PAX2
caused upregulation of HGF expression, PAX2 overexpression was
induced in PC3 cells. Overexpression of PAX2 increased HGF mRNA
expression level in PC3 cells (Fig. 1D). These ﬁndings conﬁrmed that
PAX2 increased HGF expression levels in prostate cancer cells.
3.2. HGF promoter was transcriptionally activated by PAX2
To assess whether PAX2 activated transcription on the HGF promot-
er, we performed luciferase assays using PC3 cells that were transfected
with reporter plasmids containing the HGF promoter region (−904 to
+81) fused with the luciferase gene (Fig. 2A). Cotransfection with
PAX2 expression plasmids did indeed increase relative luciferaseexpression by PAX2 in 22Rv1 cells. siRNA for PAX2 orHGFwas transfected into 22Rv1 cells
hmeasurement shows the average values of 3 independent measurements that were nor-
F-knockdown 22Rv1 cell lysates with anti-HGF or anti-PAX2 antibodies. (C) Comparative
lative to GAPDH as a control is shown for each cell line. (D) HGF gene expression in PAX2-
plasmid for 3 days. mRNA expression levels in the cells were quantiﬁed by qPCR. *P b 0.05.
Fig. 2. PAX2 upregulated HGF gene expression. (A) Luciferase assay using PC3 cells transfected with a series of constructs encoding a luciferase reporter gene driven by an upstream reg-
ulatory region of theHGF gene plasmids. FLAG-PAX2 expression plasmid or an insert-less plasmidwas cotransfectedwith the reporter plasmid for 20 h. Transcripts of ﬁreﬂy luciferase and
Renilla luciferase were quantiﬁed by qPCR. Each measurement shows the average value of 3 independent measurements that were normalized to the level of Renilla luciferase mRNA.
*P b 0.05. The same results were reproduced in independent three experiments. (B) DNA sequence of the upstream region of the human HGF gene. Underlined sequences are PAX2
and/or PAX6 binding consensus sites.
2470 T. Ueda et al. / Biochimica et Biophysica Acta 1852 (2015) 2467–2473expression through the HGF promoter region. This result indicated that
PAX2 protein upregulated HGF gene expression at the transcriptional
level. Next, to determine the region responsible for the induction of
HGF transcription by PAX2 protein, portions of the HGF gene promoterFig. 3. PAX2 interacted upstream of theHGF gene. (A) DNA sequence alignment of the upstream
and/or PAX6 binding sites. A schematic alignment of the oligonucleotides used in DNA pull-do
replacedwith other nucleotides (red characters inmt sequences). (B) DNA pull-down assay usin
(shown in Fig. 4A). (C) Luciferase assay using PC3 cells cotransfected with HGF-luc reporter pla
results were reproduced for each experiments three times.were deleted. When the luciferase gene was fused with the −637 to
+81 region, expression was activated by PAX2, whereas the−314 to
+81 region was not activated by PAX2 (Fig. 2A). These observations
suggested that the region from−637 to−314 was indispensable forregion of theHGF genes (upper sequences). Gray boxes are consensus sequences of PAX2
wn assay (bottom sequences). Six nucleotides in the PAX2 and/or PAX6 binding site were
g recombinant PAX2 protein and oligonucleotides derived from upstreamof theHGF gene
smids (wt ormt,−904–+81 of HGF gene) and FLAG-PAX2 expression plasmids. The same
2471T. Ueda et al. / Biochimica et Biophysica Acta 1852 (2015) 2467–2473activation of the HGF promoter by PAX2. PAX2 and/or PAX6 consensus
binding sites are found in this region (Fig. 2B) [23], therefore we
hypothesized that PAX2 bound to DNA around the HGF promoter.3.3. PAX2 bound to DNA in the HGF promoter
The regiondescribed above contained a PAX2 and/or PAX6 consensus
binding sequence that is conserved in several species (Fig. 3A).We used
synthetic oligonucleotides to analyze the consensus binding sites' abili-
ty to bind PAX2 and conﬁrmed that thewild-type (wt) oligowas able to
bind PAX2 (Fig. 3B). Replacement of six nucleotides with other residues
in the consensus binding sites sharply diminished PAX2 binding (mt in
Fig. 3B). Luciferase activity of the HGF promoter mediated by PAX2
was decreased by mutation in the consensus binding sites (Fig. 3C).
The results suggested that PAX2 protein activated theHGF gene through
binding to the DNA in the HGF promoter region.3.4. PAX2 associated with the HGF promoter and induced HGF gene activa-
tion through histone H3 acetylation
To determinewhether PAX2 associated with the promoter region of
HGF in prostate cancer cells, we conducted ChIP assays using anti-PAX2
antibody. The results revealed that PAX2 associated with region-b
containing the PAX2 consensus binding site (Fig. 4A). Transcriptional
activation is well known to be marked by acetylation of histones or
methylation of speciﬁc lysines (H3K4 and H3K36) [24]. Thus, we
assessedwhether the acetylation level of theHGF promoter was altered
by PAX2. The results of the ChIP assay using anti-histone acetylated-H3
antibody showed that the histone H3 acetylation level of region-b was
reduced by knockdown of PAX2 (Fig. 4C). These results suggested that
PAX2 interacted with the HGF promoter and increased histone H3
acetylation level in the region.Fig. 4. PAX2 promoted histone acetylation in the upstream region of theHGF gene. (A) Schemat
A gray box shows PAX2 and/or PAX6 consensus binding site. (B) ChIP assaywith anti-PAX2 anti
bar represents an average of 3 independent experiments as the relative intensity compared to th
in 22Rv1 cells transfected for siPAX2 for 3 days. Each experiment was reproduced three times.3.5. HGF mediated the invasive properties of prostate cancer cells
downstream of PAX2
To investigate the relationship between PAX2 and HGF in prostate
cancer cell invasion, matrigel invasion assays were performed using
22Rv1 cells. 22Rv1 cells were used as amodel of prostate cancer cell be-
havior. 22Rv1 cells are themost invasive of the prostate cancer cell lines
that we investigate previously [3]. Though cancer cell invasion was re-
duced by single knockdown of PAX2 or HGF, reduced rates of invasion
were not altered by double knockdown of both PAX2 and HGF (Fig. 5A,
B). These data raised the possibility that PAX2 and HGF functioned in
the same pathway regulating cancer cell invasion. To conﬁrm that
HGF substantially mediated the invasive properties of prostate cancer
cells downstream of PAX2, we added recombinant HGF to the medium
after knockdown of PAX2 in the invasion assay. The effect of the PAX2
knockdown on invasion was rescued by addition of recombinant HGF.
3.6. PAX2 expression positively correlated with HGF expression in prostate
cancer patients
To investigate the correlation between PAX2 and HGF expression,
mRNA expression levels of the two genes were quantiﬁed by qPCR in
tissues obtained from prostate cancer patients (Fig. 6, Table S1). In
these prostate cancer samples, there was a positive correlation between
PAX2 and HGF expression (r = 0.616). These results suggested PAX2
protein promoted prostate cancer cell invasion through induction of
HGF expression in prostate cancer patients.
4. Discussion
We previously suggested that overexpression of the PAX2 gene pro-
moted cancer cell invasion in AIPC. In this report, we showed that HGF, a
well-known regulator of cancer cell invasion, was a direct target gene ofic diagram of the humanHGF gene. Black arrows indicate ampliﬁed regions for ChIP assays.
body in 22Rv1 cells. Immunoprecipitated DNAwas ampliﬁed and quantiﬁed by qPCR. Each
e input (mean+S.D.). *P b 0.05. (C) ChIP assaywith anti-acetylated histoneH3 antibodies
Fig. 5. PAX2 enhanced invasive activity of androgen-independent prostate cancer cells upstream of the HGF pathway. (A) Invasion assay using 22Rv1 cells. 22Rv1 cells were transfected
with siRNAs for HGF or PAX2 for 2 days. Then, these cells were cultured inMatrigel invasion chamberswith orwithout 100 pM recombinantHGF for 24 h. (B) The number of invading cells
was counted. Invasion index shows the average values of 3 independent measurements, which was normalized to cell number of control inserts. *P b 0.05. The same results were
reproduced in independent three experiments.
2472 T. Ueda et al. / Biochimica et Biophysica Acta 1852 (2015) 2467–2473PAX2. PAX2 associates upstream of the HGF gene and upregulates HGF
gene expression through alteration of histone modiﬁcation.
The primary therapy formetastatic prostate cancer is blockade of the
androgen signaling pathway through the androgen receptor (AR) [25].
Though the patient responds to the therapy initially, most patients
become resistant to the therapy in a few years [25]. There are several
proposed mechanisms by which prostate cancer cells become resistant
to androgen blockade therapy. One such is activation of a signaling
pathway other than that of androgen [26]. Dysregulation of the
HGF/MET signaling pathway has been associated with emergence ofFig. 6. PAX2 expression correlated with HGF expression in prostate cancer patients. HGF
and PAX2mRNA expression levels in prostate cancer tissues (n = 19). mRNA expression
levels were quantiﬁed by qPCR. Each measurement was normalized to GAPDH mRNA
levels.prostate cancer cells resistant to androgen blockade therapy [27].
Reﬂecting the importance of HGF/MET signaling in prostate cancer pro-
gression, several clinical studies have tested new drugs targeting the
HGF/MET signal pathway [28]. Rilotumumab, a monoclonal anti-HGF
antibody, was administered to metastatic castration-resistant prostate
cancer patients in a randomized phase II study [27]. Although the
toxicities of rilotumumabweremanageable, the effectiveness was inad-
equate. A previous report using an in vitro system showed that adminis-
tration of anti-HGF antibody had no effect on the growth of 22Rv1 cells,
whereas knockdown of MET suppressed the growth of 22Rv1 cells [14].
These results suggested that the HGF/MET signaling pathway was
activated through different mechanisms in androgen-dependent and
AIPC cells. Although anti-HGF antibody could inhibit the growth of
androgen-dependent prostate cancer cells inwhich paracrine activation
of HGF/MET signaling took place and the antibody failed to block
autocrine activation of the pathway in AIPC. Our study suggested that
the PAX2/HGF pathway may be a new therapeutic target. From our ob-
servation that PAX2 overexpression induced HGF expression (Fig. 1C),
high production of PAX2 protein may be one of themechanisms under-
lying HGF expression in AIPC cells. Inhibition of such an autocrine loop
by PAX2 knockdown may be a more effective therapy than administra-
tion of HGF-antibody when AIPC patients are treated.
Understanding the mechanism of normal prostate development
may lead to the identiﬁcation of new therapies for AIPC because dysreg-
ulated function of the factors regulating normal organogenesis is associ-
ated with carcinogenesis. Several factors reportedly regulate prostate
development. Among them, AR is expressed in the urogenital sinus
mesenchyme (UGM) of the prostate at an early stage and initiates
prostatic bud formation [29]. AR is a ligand-dependent transcription
factor that exerts its function through the regulation of target gene
expression. NKX3-1 is one of the target genes of AR and it functions in
prostate development and carcinogenesis [30]. PAX2, a ligand-
independent transcription factor, is expressed in the urogenital sinus
(UGS) and regulates prostatic ductal growth and branching. HGF, a tar-
get gene of PAX2,may function in prostate development. ThoughHGF is
known to regulate the development of the liver, the role of HGF in
prostate development is unknown. HGF-knockout mice are embryonic
2473T. Ueda et al. / Biochimica et Biophysica Acta 1852 (2015) 2467–2473lethal and the phenotype in the prostate at the embryonic stage cannot
be easily examined. Examination of HGF expression in the prostate at
various developmental stages may be useful for understanding the
mechanism of prostate development and carcinogenesis.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2015.08.008.
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